Publication | Open Access

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Trametinib Versus PlaceboMedicineMelanomaImmunologyPathologyAdjuvant DabrafenibImmune Checkpoint InhibitorStage Iii MelanomaCancer TreatmentImmunotherapyOncologyRadiation OncologyMolecular Oncology